U.S. Markets close in 6 hrs

Cancer Vaccines Market Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Key Industry Forecasts to 2022

PUNE, India, April 26, 2017 /PRNewswire-iReach/ -- The Cancer Vaccines Market report "Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19" provides an in-depth analysis of the Cancer Vaccines market, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and prognosis.

Browse Complete 91 Tables and Figures, Top 9 Leading Companies Profile, spread across 183 pages available @ http://www.reportsnreports.com/reports/767638-global-cancer-vaccines-market-to-2022-robust-growth-driven-by-increasing-prevalence-new-therapeutic-vaccine-approvals-and-strong-uptake-of-treatments-targeting-cd19.html .

Cancer is anticipated to become increasingly prevalent due to aging populations and rising levels of obesity in the developed world. Cancer vaccines are being developed as a method of preventing certain types of cancer and as therapeutic treatments to treat existing cancers across a range of oncology indications. They can be used as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery.

Cancer vaccines are not perceived to have as promising a level of commercial potential as immune checkpoint inhibitors. These are a relatively new class of treatments, with the first FDA approval being granted in 2011, for Yervoy. The immune system depends on multiple checkpoints or 'immunological brakes' to avoid over activation of the immune system on healthy cells, and tumor cells often exploit these checkpoints to escape detection by the immune system. Immune checkpoint inhibitors block the proteins involved in the mechanisms behind immune evasion, allowing T-cells and the immune system to better destroy cancer cells.

Order a Single or Corporate User License Copy @ http://www.reportsnreports.com/purchase.aspx?name=767638 .

Generic penetration is currently non-existent in the cancer vaccines market, further aiding market growth. Indeed, therapeutic vaccines are a relatively new form of cancer treatment, with the first FDA approval granted to Provence in 2010. Prophylactic vaccines have not yet faced patent expiry, meaning the threat of generics/biosimilars restricting revenue growth in this market during the forecast period is low.

The cancer vaccines space will see such impressive growth over next decade for a number of reasons. There is a fairly large cancer vaccine pipeline, with over 1,200 products being developed, accounting for almost 17% of the overall oncology pipeline, the largest of any therapy area.

In-depth Assessment provides the following:

The Cancer Vaccines Market report Analyzes the oncology vaccines pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: cervical, liver, and prostate cancer and melanoma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.

Assesses the company landscape in oncology vaccines, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.

Cancer Vaccines Market report Analyzes trends in co-development and licensing deals relating to oncology vaccines products. Some of the most prominent deals are discussed in detail.

Companies mentioned in this report: Merck & Co, GSK, Novartis, Kite Pharma, Amgen, Juno Therapeutics, Valeant Pharma, Bluebird Bio, Bavarian Nordic.

Get Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=767638 .

Major Table of Content: Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Key Marketed Products

Pipeline Landscape Assessment

Multi-scenario Market Forecast to 2022

Company Analysis and Positioning

Strategic Consolidations

List of Tables

List of Figures

Related Reports:

1] Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

2] Prostate Cancer - Heat Map and Analysis

3] Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Explore more reports on Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Media Contact: Ritesh Tiwari, ReportsnReports.com, + 1 888 391 5441, sales@reportsandreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com